Secondary Logo

Most Popular Articles

Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform

Bisschop, Cornelis; ter Elst, Arja; Bosman, Lisette J.; More

Melanoma Research. 28(2):96-104, April 2018.

Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model

Kenessey, István; Kramer, Zsófia; István, Lilla; More

Melanoma Research. 28(6):536-546, December 2018.

Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2013–2016

Brzozowska, Melania; Wierzba, Waldemar; Sliwczynski, Andrzej; More

Melanoma Research. 28(1):52-55, February 2018.

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study

Ascierto, Paolo A.; Bastholt, Lars; Ferrucci, Pier F.; More

Melanoma Research. 28(4):333-340, August 2018.

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma

Hintzsche, Jennifer D.; Gorden, Nicholas T.; Amato, Carol M.; More

Melanoma Research. 27(3):189-199, June 2017.

Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma

Tarhini, Ahmad; Ghate, Sameer R.; Ionescu-Ittu, Raluca; More

Melanoma Research. 28(6):618-628, December 2018.

Sarcoid-like reactions in patients receiving modern melanoma treatment

Dimitriou, Florentia; Frauchiger, Anna L.; Urosevic-Maiwald, Mirjana; More

Melanoma Research. 28(3):230-236, June 2018.

A combination of high dose rate (10X FFF/2400 MU/min/10 MV X-rays) and total low dose (0.5 Gy) induces a higher rate of apoptosis in melanoma cells in vitro and superior preservation of normal melanocytes

Sarojini, Sreeja; Pecora, Andrew; Milinovikj, Natasha; More

Melanoma Research. 25(5):376-389, October 2015.

Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients

Tan, Sally Y.; Najita, Julie; Li, Xiaoxue; More

Melanoma Research. 29(1):70-76, February 2019.

Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma

Garbe, Claus; Hauschild, Axel; Volkenandt, Matthias; More

Melanoma Research. 18(1):61-67, February 2008.

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland

Mangana, Joanna; Cheng, Phil F.; Kaufmann, Corina; More

Melanoma Research. 27(4):358-368, August 2017.

Compromised vitamin D receptor signalling in malignant melanoma is associated with tumour progression and mitogen-activated protein kinase activity

Hutchinson, Peter E.; Halsall, John A.; Popovici, Silvia; More

Melanoma Research. 28(5):410-422, October 2018.

Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors

Chesney, Jason; Imbert-Fernandez, Yoannis; Telang, Sucheta; More

Melanoma Research. 28(3):250-255, June 2018.

LINE-1 hypermethylation in peripheral blood of cutaneous melanoma patients is associated with metastasis

De Araújo, Érica S.S.; Kashiwabara, André Y.; Achatz, Maria I.W.; More

Melanoma Research. 25(2):173-177, April 2015.

Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2

Nagayama, Hitomi; Sato, Katsuaki; Morishita, Mariko; More

Melanoma Research. 13(5):521-530, October 2003.

Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients

Vereecken, Pierre; Awada, Ahmad; Suciu, Stefan; More

Melanoma Research. 19(5):316-320, October 2009.

Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials

Menshawy, Amr; Eltonob, Abdelrahman A.; Barkat, Sarah A.; More

Melanoma Research. 28(5):371-379, October 2018.

Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma – Prima study

Espinosa, Enrique; Soriano, Virtudes; Malvehy, Josep; More

Melanoma Research. 26(3):278-283, June 2016.

Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells

Scaini, Maria Chiara; Pigozzo, Jacopo; Pizzi, Marco; More

Melanoma Research. 29(1):89-94, February 2019.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

Gonzalez-Cao, Maria; Mayo de las Casas, Clara; Jordana Ariza, Nuria; More

Melanoma Research. 28(3):195-203, June 2018.

The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis

Danish, Hasan H.; Patel, Kirtesh R.; Switchenko, Jeffrey M.; More

Melanoma Research. 26(6):595-603, December 2016.

MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

Guadagni, Stefano; Fiorentini, Giammaria; Clementi, Marco; More

Melanoma Research. 27(5):439-447, October 2017.

Show: